The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison

A P Prayle, K Jain, D J Touw, B C P Koch, A J Knox, A Watson, A R Smyth, A P Prayle, K Jain, D J Touw, B C P Koch, A J Knox, A Watson, A R Smyth

Abstract

Background: Circadian variation in renal toxicity of aminoglycosides has been demonstrated in animal and human studies. People with CF are frequently prescribed aminoglycosides. Altered pharmacokinetics of aminoglycosides are predictive of toxicity.

Aim: To investigate whether the time of day of aminoglycoside administration modulates renal excretion of tobramycin and toxicity in children with CF. To determine whether circadian rhythms are disrupted in children with CF during hospital admission.

Methods: Children (age 5-18years) with CF scheduled for tobramycin therapy were randomly allocated to receive tobramycin at 0800 or 2000h. Serum tobramycin levels were drawn at 1h and between 3.5 and 5h post-infusion between days 5 and 9 of therapy. Melatonin levels were measured serially at intervals from 1800h in the evening until 1200h on the next day. Circadian rhythm was categorised as normal when dim light melatonin onset was demonstrated between 1800 and 2200h and/or peak melatonin levels were observed during the night. Weight and spirometry were measured at the start and end of the therapy. Urinary biomarkers of kidney toxicity (KIM1, NAG, NGAL, IL-18 and CysC) were assayed at the start and end of the course of tobramycin.

Results: Eighteen children were recruited to the study. There were no differences in renal clearance between the morning and evening groups. The increase in urinary KIM-1 was greater in the evening dosage group compared to the morning group (mean difference, 0.73ng/mg; 95% CI, 0.14 to 1.32; p=0.018). There were no differences in the other urinary biomarkers. There was normal circadian rhythm in 7/11 participants (64%).

Conclusions: Renal elimination of tobramycin was not affected by the time of day of administration. Urinary KIM-1 raises the possibility of greater nephrotoxicity with evening administration. Four children showed disturbed circadian rhythm and high melatonin levels (ClinicalTrials.gov NCT01207245).

Keywords: Aminoglycosides; Circadian rhythm; Cystic fibrosis; Toxicity.

Copyright © 2015. Published by Elsevier B.V.

Figures

Graphical abstract
Graphical abstract
Fig. 1
Fig. 1
Consort diagram of included participants.
Fig. 2
Fig. 2
Increase in urinary KIM1 evening versus morning administration group. Urinary KIM1 was collected at the start and end of therapy. Lines represent the mean and standard error of the mean. Levels were normalised to urinary creatinine to control for urinary concentration (ng KIM1 per mg creatinine).
Fig. 3
Fig. 3
Melatonin profiles. Each plot represents the profile for an individual participant. Purple background (a–g): normal; Yellow Background (h–k): abnormal. For definitions of normal and abnormal, please see methods.

References

    1. Trust U.K.C.F. CF Trust; 2014. UK Cystic Fibrosis Registry.
    1. Bertenshaw C., Watson A.R., Lewis S., Smyth A., Bertenshaw C., Watson A.R. Survey of acute renal failure in patients with cystic fibrosis in the UK. Thorax. 2007;62(6):541–545. [2007 June 1]
    1. Smyth A., Lewis S., Bertenshaw C., Choonara I., McGaw J., Watson A. Case–control study of acute renal failure in patients with cystic fibrosis in the UK. Thorax. 2008;63(6):532–535. [2008 June 1]
    1. Al-Aloul M., Miller H., Alapati S., Stockton P., L M., Walshaw M. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol. 2005;39(1):15–20.
    1. Touw D.J., Vinks A.A., Heijerman H.G., Bakker W. Validation of tobramycin monitoring in adolescent and adult patients with cystic fibrosis. Ther Drug Monit. Feb 1993;15(1):52–59. [PubMed PMID: 8451782. Epub 1993/02/01. eng.]
    1. Smyth A., Tan K.H.V., Hyman-Taylor P., Mulheran M., Lewis S., Stableforth D. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis—the TOPIC study: a randomised controlled trial. Lancet. 2005;365(9459):573–578.
    1. Smyth A.R., Campbell E.L. Prescribing practices for intravenous aminoglycosides in UK Cystic Fibrosis clinics: A questionnaire survey. J Cyst Fibros. Jul 2014;13(4):424–427. [PubMed PMID: ISI:000338814400013. English.]
    1. Pariat C., Courtois P., Cambar J., Piriou A., Bouquet S. Circadian variations in the renal toxicity of gentamicin in rats. Toxicol Lett. Feb 1988;40(2):175–182. [PubMed PMID: ISI:A1988L918900010. English.]
    1. Lin L.S., Grenier L., Theriault G., Gourde P., Yoshiyama Y., Bergeron M.G. Nephrotoxicity of low-doses of tobramycin in rats—Effect of the time of administration. Life Sci. 1994;55(3):169–177. [PubMed PMID: ISI:A1994NQ58000002. English.]
    1. Bleyzac N., Allard-Latour B., Laffont A., Mouret J., Jelliffe R., Maire P. Diurnal changes in the pharmacokinetic behavior of amikacin. Ther Drug Monit. Jun 2000;22(3):307–312. [PubMed PMID: 10850398. eng.]
    1. Prins J.M., Weverling G.J., van Ketel R.J., Speelman P. Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients. Clin Pharmacol Ther. 1997;62(1):106–111.
    1. Lucht F., Tigaud S., Esposito G., Cougnard J., Fargier M.P., Peyramond D. Chronokinetic study of netilmicin in man. Eur J Clin Pharmacol. 1990;39(2):199–201. [PubMed PMID: ISI:A1990DV45200023. English.]
    1. Elting L., Bodey G.P., Rosenbaum B., Fainstein V. Circadian variation in serum amikacin levels. J Clin Pharmacol. Sep 1990;30(9):798–801. [PubMed PMID: ISI:A1990EA46900005. English.]
    1. Fauvelle F., Perrin P., Belfayol L., Boukari M., Cherrier P., Bosio A.M. Fever and associated changes in glomerular filtration rate erase anticipated diurnal variations in aminoglycoside pharmacokinetics. Antimicrob Agents Chemother. 1994;38(3):620–623. [1994 March 1]
    1. Touw D.J., Knox A.J., Smyth A. Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis. J Cyst Fibros. Sep 2007;6(5):327–333. [PubMed PMID: 17276147. Epub 2007/02/06. eng.]
    1. Klerman E.B., Gershengorn H.B., Duffy J.F., Kronauer R.E. Comparisons of the variability of three markers of the human circadian pacemaker. J Biol Rhythms. Apr 2002;17(2):181–193. [PubMed PMID: ISI:000174719700009. English.]
    1. UK CF Trust Antibiotic Working Group . Cystic Fibrosis Trust; 2009. Antibiotic treatment for cystic fibrosis. [2009. Report No.]
    1. der Heijden KB Van, Smits M.G., Van Someren E.J.W., Gunning W.B. Prediction of melatonin efficacy by pretreatment dim light melatonin onset in children with idiopathic chronic sleep onset insomnia. J Sleep Res. Jun 2005;14(2):187–194. [PubMed PMID: WOS:000229278600009. English.]
    1. Touitou Y., Auzeby A., Camus F., Djeridane Y. Daily profiles of salivary and urinary melatonin and steroids in healthy prepubertal boys. J Pediatr Endocrinol Metab. Nov 2009;22(11):1009–1015. [PubMed PMID: WOS:000273080400004. English.]
    1. Praninskiene R., Dumalakiene I., Kemezys R., Mauricas M., Jucaite A. Diurnal melatonin patterns in children: ready to apply in clinical practice? Pediatr Neurol. Feb 2012;46(2):70–76. [PubMed PMID: WOS:000299863700002. English]
    1. Schwartz G.J., Haycock G.B., Edelmann C.M., Jr., Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics. Aug 1976;58(2):259–263. [PubMed PMID: 951142. Epub 1976/08/01. eng.]
    1. Miller M.R., Hankinson J., Brusasco V., Burgos F., Casaburi R., Coates A. Standardisation of spirometry. Eur Respir J. Aug 2005;26(2):319–338. [PubMed PMID: ISI:000230874000021. English]
    1. R Development Core Team . R Foundation for Statistical Computing; Vienna: 2012. R: A language and environment for statistical computing. 2.15.0 ed.
    1. de Groot R., Smith A.L. Antibiotic pharmacokinetics in cystic-fibrosis—Differences and clinical-significance. Clin Pharmacokinet. Oct 1987;13(4):228–253. [PubMed PMID: ISI:A1987K457500002. English]
    1. Koopman M.G., Koomen G.C.M., Krediet R.T., Demoor E.A.M., Hoek F.J., Arisz L. Circadian-rhythm of glomerular-filtration rate in normal individuals. Clin Sci. Jul 1989;77(1):105–111. [PubMed PMID: ISI:A1989AB99600017. English]
    1. McWilliam S.J., Antoine D.J., Sabbisetti V., Turner M.A., Farragher T., Bonventre J.V. Mechanism-based urinary biomarkers to identify the potential for aminoglycoside-induced nephrotoxicity in premature neonates: a proof-of-concept study. PLoS One. 2012;7(8):e43809. [PubMed PMID: 22937100. Pubmed Central PMCID: 3427159. Epub 2012/09/01. eng.]
    1. McWilliam S.J., Antoine D.J., Smyth R.L., Pirmohamed M. Association of urinary kidney injury molecule-1 with aminoglycoside exposure in children with cystic fibrosis. J Cyst Fibros. 2014;6(13, Supplement 2(0)):S63. [abstract]
    1. Ichimura T., Bonventre J.V., Bailly V., Wei H., Hession C.A., Cate R.L. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem. 1998;273(7):4135–4142. [1998 February 13]
    1. Ichimura T., Hung C.C., Yang S.A., Stevens J.L., Bonventre J.V. Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Renal Physiol. 2004;286(3):F552–F563. [2004 March 1]
    1. Vanmassenhove J., Vanholder R., Nagler E., Van Biesen W. Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature. Nephrol Dial Transplant. Feb 2013;28(2):254–273. [PubMed PMID: ISI:000316119500007. English]
    1. Shao X., Tian L., Xu W., Zhang Z., Wang C., Qi C. Diagnostic value of urinary kidney injury molecule 1 for acute kidney injury: a meta-analysis. PLoS One. 2014;9(1):e84131. [PubMed PMID: 24404151. Pubmed Central PMCID: 3880280]

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner